Yatharth Hospital reported a significant 23% increase in profits and a substantial 47% growth in revenues for Q4 compared to the same period last year, signaling strong financial performance.

Three prominent companies - Suzlon, RVNL, and Yatharth Hospital - are set to release their Q4 financial results on May 25, 2026, creating an important day for investors interested in these firms' performance.

Analyst Aakash Shah predicts a positive outlook for RPEL, INGERRAND, and YATHARTH, based on strong technical indicators and potential gains. The analyst suggests potential price targets of ₹1015 for RPEL, ₹4800 for INGERRAND, and ₹935 for YATHARTH. Support levels are provided to manage risks in these investments.

Yatharth Hospital has reached its highest point ever, indicating strong growth potential with a recommended buy-in at 862. Analysts predict the stock could climb to 935, but suggest setting a safety limit at 816.

Yatharth Hospital's Q4 & FY26 audited results reveal a revenue growth of ₹5,918.8 million and net profit of ₹954.1 million, as confirmed by MSKA. The robust financial performance indicates a promising future for the hospital.

Yatharth Hospital has announced its intent to purchase a Gurugram hospital asset from RNY Healthcare for INR 100 crores. The acquisition encompasses 1.3 acres of land and an additional 250 beds, with the deal expected to close within 45 days.